Urinary hypoxanthine and pseudouridine as indicators of tumor development in mesothelioma-transplanted nude mice.
A human mesothelioma was heterotransplanted to nude mice, and the urinary excretions of hypoxanthine, xanthine, pseudouridine, orotic acid, 7-methylguanine, and 1-methylhypoxanthine have been followed before and after the tumor transplantation. The compounds were measured by means of isotachophoresis, which has been found a rapid and precise method. The tumor reached maximum size within 30 days, and at this time a significantly increased excretion of pseudouridine and hypoxanthine was observed. Tumor growth was stopped by chemotherapy (vincristine, cyclophosphamide, prednisolone, and Adriamycin), and corresponding to this, a decrease occurred in both pseudouridine and hypoxanthine excretion to normal values.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D019271:Hypoxanthine; D007042:Hypoxanthines / Q000652:urine*; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy / Q000473:pathology / Q000652:urine*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011239:Prednisolone / Q000627:therapeutic use; D011560:Pseudouridine / Q000652:urine*; D014529:Uridine / Q000031:analogs & derivatives*; D014750:Vincristine / Q000627:therapeutic use
D007042:Hypoxanthines; D011560:Pseudouridine; D019271:Hypoxanthine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D014529:Uridine